Regeneron Pharmaceuticals
REGN
1,388 hedge funds and large institutions have $97.5B invested in Regeneron Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 141 funds opening new positions, 540 increasing their positions, 462 reducing their positions, and 70 closing their positions.
101% more first-time investments, than exits
New positions opened: 141 | Existing positions closed: 70
17% more repeat investments, than reductions
Existing positions increased: 540 | Existing positions reduced: 462
4% more funds holding
Funds holding: 1,331 → 1,388 (+57)
0.32% less ownership
Funds ownership: 86.89% → 86.56% (-0.32%)
1% less capital invested
Capital invested by funds: $98.9B → $97.5B (-$1.42B)
21% less funds holding in top 10
Funds holding in top 10: 29 → 23 (-6)
22% less call options, than puts
Call options by funds: $1.41B | Put options by funds: $1.8B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$979M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$381M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$363M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$272M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$236M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$877M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$691M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$379M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$319M |
| 5 |
Morgan Stanley
New York
|
-$173M |
REGN Hedge Fund Activity: Q3 2024 in Review
1,388 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2024, worth a combined $97.5B — down 1.4% from $98.9B a quarter earlier.
Buyers outnumbered sellers: 141 funds opened new REGN positions and 70 closed out — a net gain of 71 holders — while 540 added to existing stakes and 462 trimmed.
The largest buyer was International Assets Investment Management, adding an estimated $979M. The largest seller was JP Morgan Chase, cutting an estimated $877M.
- 1,388 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2024, up from 1,331 in Q2 2024.
- Funds reported $97.5B of Regeneron Pharmaceuticals stock for Q3 2024, down 1.4% quarter-over-quarter.
- 141 funds opened new Regeneron Pharmaceuticals positions in Q3 2024 and 70 closed out, a net change of +71 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2024 was International Assets Investment Management, an estimated $979M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2024 was JP Morgan Chase, an estimated $877M sold.
Based on aggregated 13F filings for Q3 2024.